Brain Photobiomodulation: Searching for Predictive Target Engagement

A special issue of Photonics (ISSN 2304-6732). This special issue belongs to the section "Biophotonics and Biomedical Optics".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 4815

Special Issue Editors

1. Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital, 149 13th Street (2612), Boston, MA 02129, USA
2. Harvard Medical School, Boston, MA, USA
Interests: transcranial photobiomodulation; low-level light therapy; major depressive disorder; anxiety disorders; Alzheimer’s disease; Down syndrome; bipolar disorder; brain injury; sexual dysfunction

E-Mail Website
Guest Editor
1. Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital, 149 13th Street (2612), Boston, MA 02129, USA
2. Harvard Medical School, Boston, MA, USA
3. Department of Anatomy, Institute of Biomedical Sciences, University of Sao Paulo (USP), Sao Paulo, Brazil
Interests: transcranial photobiomodulation; low-level light therapy; major depressive disorder; anxiety disorders; pain; diabetic neuropathy; chemotherapy-induced neuropathy

Special Issue Information

Dear Colleagues,

The goal of this Special Issue is to bring together a collection of papers—either preclinical or clinical studies—to elucidate the effects of t-PBM on neurophysiological targets. The latter might include neuroinflammation, oxidative stress, and neurogenesis as well as neurometabolites, brain waves, and connectivity (the list is not exhaustive but rather an exemplification). It will be critically important to accurately report the t-PBM parameters and the expected light deposition at the target as well as the treatment safety and tolerability.

We welcome the submission of manuscripts including, but not limited to, the following topics:

  • Applications of t-PBM in animal models of stress-related disorders, especially depression and anxiety, considering pathobiological insights into genetic vulnerability, altered hypothalamic–pituitary–adrenal (HPA) axis activity, monoamines dysfunction, deficiency of cerebral blood flow (CBF) in specific brain regions, neurotoxic and neurotrophic processes, reduced gamma-aminobutyric acid (GABA) activity, dysregulation of the glutamate system, impaired circadian rhythms, etc.;
  • Preclinical and clinical studies involving t-PBM applications for neurodegenerative diseases (e.g., Alzheimer’s and Parkinson’s) and neuropsychiatric disorders (e.g., major depressive disorder (MDD)), thus aiming to target specific regions of the central nervous system (e.g., hippocampus, amygdala, prefrontal cortex (PFC), and anterior cingulate cortex (ACC)). Special focus will be given (but it is not restricted) to analyses involving cutting-edge technologies such as fMRI, accompanied by clinical measures of mood, cognition, suicidal ideation, sleep, anhedonia, etc.;
  • Methodological and study protocol papers that advance the field by exemplifying the best approaches for t-PBM studies with specific neurophysiological targets will also be considered.

Dr. Paolo Cassano
Dr. Willians Fernando Vieira
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Photonics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • transcranial photobiomodulation
  • low-level light therapy
  • major depressive disorder
  • anxiety disorders
  • Alzheimer’s disease
  • Down syndrome
  • bipolar disorder
  • brain injury
  • sexual dysfunction

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

9 pages, 582 KiB  
Communication
Trajectories of Depressive Individual Symptoms over Time during Transcranial Photobiomodulation
by Minoru Urata, Paolo Cassano, Richard Norton, Katelyn M. Sylvester, Koichiro Watanabe, Dan V. Iosifescu and Hitoshi Sakurai
Photonics 2023, 10(12), 1324; https://doi.org/10.3390/photonics10121324 - 29 Nov 2023
Viewed by 1158
Abstract
Transcranial photobiomodulation (t-PBM) is an innovative, non-invasive treatment for depression. This study aimed to investigate the changes in individual depressive symptoms during t-PBM treatment and identify the symptoms that improved in those who responded to treatment. The research analyzed data from two trials, [...] Read more.
Transcranial photobiomodulation (t-PBM) is an innovative, non-invasive treatment for depression. This study aimed to investigate the changes in individual depressive symptoms during t-PBM treatment and identify the symptoms that improved in those who responded to treatment. The research analyzed data from two trials, the Evaluation of Light-emitting diodes Therapeutic Effect in Depression-2 and -3, focusing on patients with major depressive disorder. The patients received t-PBM treatment on the F3 and F4 regions of the scalp over eight weeks, with symptoms assessed weekly using the Quick Inventory for Depression Symptomatology (QIDS). A response was defined as a 50% or greater reduction in the QIDS score at eight weeks from baseline. Out of the 21 patients analyzed, 4 responded at eight weeks. Neurovegetative symptoms, including sleep disturbances and change in appetite, improved in ≥50% of the patients who had these symptoms at baseline. However, core depressive symptoms, including a depressed mood and lack of energy, persisted in about 80–90% of the patients. The responders showed a more than 75% improvement in these core depressive symptoms. These findings suggest that t-PBM treatment may uniquely alleviate certain neurovegetative symptoms in depression, and the improvement in core depressive symptoms might be linked to a clinical response to this treatment. Full article
(This article belongs to the Special Issue Brain Photobiomodulation: Searching for Predictive Target Engagement)
Show Figures

Figure 1

18 pages, 1280 KiB  
Article
Grant Report on the Transcranial near Infrared Radiation and Cerebral Blood Flow in Depression (TRIADE) Study
by Dan V. Iosifescu, Katherine A. Collins, Aura Hurtado-Puerto, Molly K. Irvin, Julie A. Clancy, Allison M. Sparpana, Elizabeth F. Sullivan, Zamfira Parincu, Eva-Maria Ratai, Christopher J. Funes, Akila Weerasekera, Jacek P. Dmochowski and Paolo Cassano
Photonics 2023, 10(1), 90; https://doi.org/10.3390/photonics10010090 - 13 Jan 2023
Cited by 2 | Viewed by 3017
Abstract
We report on the rationale and design of an ongoing National Institute of Mental Health (NIMH) sponsored R61-R33 project in major depressive disorder (MDD). Current treatments for MDD have significant limitations in efficacy and side effect burden. There is a critical need for [...] Read more.
We report on the rationale and design of an ongoing National Institute of Mental Health (NIMH) sponsored R61-R33 project in major depressive disorder (MDD). Current treatments for MDD have significant limitations in efficacy and side effect burden. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. This project focuses on the adjunctive use of the transcranial photobiomodulation (tPBM) with near-infrared (NIR) light for the treatment of MDD. tPBM with NIR light penetrates robustly into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow (CBF). In the R61 phase, we will conduct target engagement studies to demonstrate dose-dependent effects of tPBM on the prefrontal cortex (PFC) CBF, using the increase in fMRI blood-oxygenation-level-dependent (BOLD) signal levels as our Go/No-go target engagement biomarker. In the R33 phase, we will conduct a randomized clinical trial of tPBM vs. sham in MDD to establish the target engagement and evaluate the association between changes in the biomarker (BOLD signal) and changes in clinical symptoms, while also collecting important information on antidepressant effects, safety, and tolerability. The study will be done in parallel at New York University/the Nathan Kline Institute (NYU/NKI) and at Massachusetts General Hospital (MGH). The importance of this study is threefold: 1. it targets MDD, a leading cause of disability worldwide, which lacks adequate treatments; 2. it evaluates tPBM, which has a well-established safety profile and has the potential to be safe in at-home administration; and 3. it uses fMRI BOLD changes as a target engagement biomarker. If effects are confirmed, the present study will both support short-term clinical development of an easy to scale device for the treatment of MDD, while also validating a biomarker for the development of future, novel modulation strategies. Full article
(This article belongs to the Special Issue Brain Photobiomodulation: Searching for Predictive Target Engagement)
Show Figures

Figure 1

Back to TopTop